Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
3.490
-0.060 (-1.69%)
At close: Feb 27, 2026, 4:00 PM EST
3.470
-0.020 (-0.57%)
After-hours: Feb 27, 2026, 7:43 PM EST
Neumora Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Neumora Therapeutics stock have an average target of 8.00, with a low estimate of 1.00 and a high estimate of 18. The average target predicts an increase of 129.23% from the current stock price of 3.49.
Analyst Consensus: Buy
* Price targets were last updated on Jan 12, 2026.
Analyst Ratings
The average analyst rating for Neumora Therapeutics stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 2 | 3 | 4 |
| Hold | 3 | 2 | 2 | 1 | 1 | 1 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Feb 17, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $8 | Buy | Initiates | $8 | +129.23% | Jan 12, 2026 |
| RBC Capital | RBC Capital | Hold → Buy Upgrades $4 → $7 | Hold → Buy | Upgrades | $4 → $7 | +100.57% | Dec 1, 2025 |
| Stifel | Stifel | Hold Maintains $2 → $3 | Hold | Maintains | $2 → $3 | -14.04% | Nov 17, 2025 |
| Needham | Needham | Strong Buy Maintains $6 → $8 | Strong Buy | Maintains | $6 → $8 | +129.23% | Oct 28, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.45
from -1.53
EPS Next Year
-1.03
from -1.45
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.42 | -0.82 | ||||
| Avg | -1.45 | -1.03 | ||||
| Low | -1.44 | -1.42 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.